number of patient | age/sex/BMI | age/sex/BMI transplanted organ | principal disease | prior to SOT hospitalization/ATB therapy | immunological risk | immunosuppression | antibiotic prophylaxis | complication | therapy | antibiotic therapy | LOS [days] | outcome |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 60/male/26.6 | kidney | chronic kidney disease, diabetic nephropathy, kidney transplantation 4 years ago, early graftectomia due to renal vein thrombosis, cardiac anamnesis: tricuspid valve repair due to regurgitation, atrial fibrillation (warfarine), EF LV 50%), habitual hypotension (midodrine), hemodialysis (AV shunt) | no/no | high 2nd kidney transplantation, PRA act 0%, max 14% | thymoglobuline and methylprednisolone (induction), thymoglobuline, tacrolimus, mycophenolate mofetil, prednisone, withdrawal on the 3rd day | cefuroxime (2 days) | early hemodynamic instability, left heart insuficiency, arythmia, sepsis, visceral ischemia | surgery, inotropes, antiarythmics, therapy of the septic shock acording to guidleines, CVVHD, mechanical ventilation for 48 h | since 2nd postoperative day meropenem 2 g á 8 h, amikacin 2 g á 24 h | 3 | death on the 2nd day after SOT, sepsis, multiorgan failure |
2 | 32/male/25.1 | kidney | chronic kidney disease, chronic glomerulonephritis, previous 2 kidney transplantations, peritoneal dialysis, 2 episodes of peritonitis | no/no | high high level of DSA, PRA act 36%, max 79% plasmapheresis before the transplantation | thymoglobuline (3 doses), intravenous immunoglobuline (3 doses), tacrolimus, mycophenolate mofetil, prednisone | cefuroxime (2 days) | haemorrhage, strangulated sigma loop around CAPD catether, haemorrhagic shock | surgery, therapy of circulatory shock, CVVHD, mechanical ventilation for 52 h | since 2nd postoperative day meropenem 2 g á 8 h, metronidazole 500 mg á 8 h | 4 | death on the 3th day after SOT, sepsis, multiorgan failure |
3 | 49/male/23.1 | liver | HCV related liver cirrhosis Child-Pugh C, portal hypertension, hepatorenal syndrome, ascites, encephalopathy | yes/yes | low, PRA 0% | methylprednisolone (induction), tacrolimus, mycophenolate mofetil, prednisone | piperacilin/tazobactam (3 days) | none | usual postoperative care, early extubation | since 3rd postoperative day meropenem 1 g á 8 h (for 10 days) | 22 | alive (2018) with good graft function |
4 | 59/female/25.8 | pancreas islets | labile diabetes mellitus type I, daily episodes of hypoglycemia, chronic kidney disease, cholestasis of the liver | no/no | low, PRA act 0%, max 13% | thymoglobuline and methylprednisolone (induction), tacrolimus, rapamycine – with drawal on the 2nd day | piperacilin/tazobactam (3 days) | haemorrhage, pneumonia, haemorrhagic and septic shock, acute kidney injury and multiorgan failure | several surgeries, therapy of circulatory shock, CVVHD, intermitent dialysis, mechanical ventilation for 540 h, tracheostomy | piperacilin/tazobactam 2,25 g á 6 h, on the 4th postoperative day changed to meropenem 1 g á 6 h, amikacin acording to serum level (for 10 days) | 81 | alive (2018), early failure of the transplanted islets, 2nd successfull islets transplantation in 2018 |
5 | 40/male/28.4 | heart | dilatation cardiomyopathy, EF LV < 20%, pulmonary hypertension, ICD, chronic kidney disease | yes/yes | low, PRA 0% | thymoglobuline, methylprednisolone, and mycophenolate mofetil (induction), thymoglobuline, tacrolimus, methylpredisolone, mycophenolate mofetil | cefriaxone (3 days) | none | usual postoperative care, mechanical ventilation for 13 h | since 2nd postoperative day meropenem 1 g á 6 h (for 10 days) | 40 | alive (2018), good graft function |